Panmure Gordon Analyst Dr Mike Mitchell this morning said about Immupharma PLC “This morning ImmuPharma has announced the commencement of dosing in the first European patients in the company’s pivotal Phase III clinical study for Lupuzor™. This means that both US and European sites are now dosing patients in the Phase III trial (recruitment is expected in up to 45 investigator sites) and with Lupus continuing to represent a major unmet medical need we consider the ongoing demand for an effective treatment – highlighted by still torpid sales of GSK’s Benlysta – represents a major opportunity for ImmuPharma and Lupuzor™. “
Learning About Lupus
May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system